Accordion 2
-
[Header/accordion copy]:
Comment 1: PAAB code 2.4: APS must reflect an attitude of caution with respect to drug usage, with emphasis on rational drug therapy and proper patient selection for the advertised product. “FLEXimab provides a low 14.5% anemia risk [Ref. PM pg. 6A]” does not reflect an attitude of caution, please revise. In addition, it is overly selective. (Section 5.12)[Subhead/accordion copy]:
Comment 2: “Well-established safety profile [+]” In section 2.6.1 it notes that the Code does not accept statements that claim directly, or indirectly, 100% clinical efficacy or safety. We question “well established” as implying 100% clinical safety. Please revise[Header and Subhead accordion copy]
Comment 3: Please note safety profile claims should be accompanied by the most common adverse events from the TMA within the APS. Consider removing accordion or using claim-neutral header. See https://www.paab.ca/resources/marketing-benefit-claims-what-are-they-and-what-level-of-support-do-they-require/.[Table copy]: [Ref. PM Pg 6A]
Comment 4: Anemia, there is an error in column 2, row 3. “14.6 should be 14.5”